Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria

12 novembre 2026 aggiornato da: Do Thanh Sang, University of Medicine and Pharmacy at Ho Chi Minh City

Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria

This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.

The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.

Panoramica dello studio

Descrizione dettagliata

This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.

The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.

Tipo di studio

Interventistico

Iscrizione (Stimato)

124

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Sang Thanh Do, MD, MSc
  • Numero di telefono: +84 948 561 030
  • Email: dtsang@ump.edu.vn

Luoghi di studio

      • Ho Chi Minh City, Vietnam
        • Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
      • Ho Chi Minh City, Vietnam
        • Le Van Thinh Hospital, Department of Dermatology
      • Ho Chi Minh City, Vietnam
        • University Medical Center Ho Chi Minh City, Branch 3

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 years or older and willing to provide written informed consent.
  • Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
  • UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
  • No previous thread embedding acupuncture.

Exclusion Criteria:

  • Urticaria with an identified cause, including physical or mechanical urticaria.
  • Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
  • Cutaneous mast cell disease or erythema multiforme.
  • Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
  • Other chronic pruritic skin disease that could interfere with assessment.
  • History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
  • Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
  • Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
  • H1 antihistamine use above the recommended dose within 3 days before screening.
  • Psychotropic medication within the preceding month.
  • Malignancy or severe endocrine disorder.
  • Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
  • Severe debilitation with reduced immune resistance.
  • Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
  • Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
  • A nonabsorbable implant at the intended procedure site.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study.
  • Participation in another clinical trial in the preceding 3 months.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: PDO Thread Embedding Acupuncture Plus Cetirizine

Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment.

An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

Comparatore fittizio: Sham Thread Embedding Acupuncture Plus Cetirizine

Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment.

Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
Lasso di tempo: Baseline and week 4

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and week 4

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in UAS7 at Weeks 2 and 8
Lasso di tempo: Baseline and weeks 2 and 8

UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2 and 8
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
Lasso di tempo: Baseline and weeks 2, 4, and 8

Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline.

Baseline and weeks 2, 4, and 8
Change From Baseline in Serum Total Immunoglobulin E (IgE)
Lasso di tempo: Baseline and week 4

Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline.

Baseline and week 4
Proportion of Participants With Adverse Events
Lasso di tempo: From baseline through week 8

The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria.

From baseline through week 8
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
Lasso di tempo: Weeks 4 through 8

Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up.

Weeks 4 through 8
Number of Rescue Cetirizine Tablets Used
Lasso di tempo: From baseline through week 4

The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups.

From baseline through week 4

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
Lasso di tempo: Baseline and week 4

A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site.

Baseline and week 4

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2027

Completamento primario (Stimato)

1 febbraio 2029

Completamento dello studio (Stimato)

1 marzo 2029

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi